NASDAQ:ATOS - Atossa Genetics Stock Price, Price Target & More

$3.52 +3.16 (+877.78 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$0.36
Today's Range$3.40 - $4.29
52-Week Range$0.22 - $4.29
Volume403,099 shs
Average Volume4.84 million shs
Market Capitalization$11.58 million
P/E Ratio-1.42
Dividend YieldN/A
Beta2.97

About Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATOS
CUSIPN/A
Phone866-893-4927

Debt

Debt-to-Equity RatioN/A
Current Ratio6.47%
Quick Ratio6.47%

Price-To-Earnings

Trailing P/E Ratio-1.42
Forward P/E RatioInfinity
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.22 per share
Price / Book16.00

Profitability

EPS (Most Recent Fiscal Year)($2.49)
Net Income$-8,120,000.00
Net MarginsN/A
Return on Equity-231.77%
Return on Assets-170.35%

Miscellaneous

Employees7
Outstanding Shares31,820,000

How to Become a New Pot Stock Millionaire

Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?

Shares of Atossa Genetics reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.

How were Atossa Genetics' earnings last quarter?

Atossa Genetics (NASDAQ:ATOS) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.20. View Atossa Genetics' Earnings History.

When is Atossa Genetics' next earnings date?

Atossa Genetics is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Atossa Genetics.

What price target have analysts set for ATOS?

1 Wall Street analysts have issued 1 year price objectives for Atossa Genetics' stock. Their predictions range from $2.00 to $2.00. On average, they expect Atossa Genetics' stock price to reach $2.00 in the next year. View Analyst Ratings for Atossa Genetics.

Who are some of Atossa Genetics' key competitors?

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the folowing people:
  • Dr. Steven C. Quay M.D., Ph.D., FCAP, Chairman, Chief Exec. Officer, Pres and Treasurer (Age 67)
  • Mr. Kyle Guse, Chief Financial Officer, Gen. Counsel and Sec. (Age 54)
  • Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
  • Mr. Pieter Van Der Poel, VP of European Commercial Operations (Age 55)
  • Dr. Jack Cuzick Ph.D., FRS, FMedSci, FRCP (hon), Scientific Advisor

Has Atossa Genetics been receiving favorable news coverage?

News coverage about ATOS stock has trended somewhat negative on Friday, according to Accern. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atossa Genetics earned a media sentiment score of -0.01 on Accern's scale. They also gave media coverage about the company an impact score of 47.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Atossa Genetics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of ATOS stock can currently be purchased for approximately $3.52.

How big of a company is Atossa Genetics?

Atossa Genetics has a market capitalization of $11.58 million. The company earns $-8,120,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Atossa Genetics employs 7 workers across the globe.

How can I contact Atossa Genetics?

Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 866-893-4927 or via email at [email protected]


MarketBeat Community Rating for Atossa Genetics (ATOS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Atossa Genetics (NASDAQ:ATOS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Atossa Genetics in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible downside of 43.18%. The high price target for ATOS is $2.00 and the low price target for ATOS is $2.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00N/AN/A
Price Target Upside: 43.18% downside525.00% upsideN/AN/A

Atossa Genetics (NASDAQ:ATOS) Consensus Price Target History

Price Target History for Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics (NASDAQ:ATOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018Maxim GroupInitiated CoverageBuy -> Buy$2.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Atossa Genetics (NASDAQ:ATOS) Earnings History and Estimates Chart

Earnings by Quarter for Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics (NASDAQ:ATOS) Earnings Estimates

Next Year EPS Consensus Estimate: $-0.35 EPS

Atossa Genetics (NASDAQ ATOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.06)N/AView Earnings Details
11/14/2017Q3 2017($0.29)($0.17)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.44)($0.64)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.45)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.77)ViewN/AView Earnings Details
11/14/2016Q316($1.28)$0.07ViewN/AView Earnings Details
8/12/2016Q2($0.07)($0.05)ViewN/AView Earnings Details
5/5/2016Q116($0.07)ViewN/AView Earnings Details
11/12/2015Q315($0.11)($0.15)$2.80 million$0.77 millionViewListenView Earnings Details
8/6/2015Q215($0.12)($0.11)$2.05 million$2.69 millionViewN/AView Earnings Details
5/13/2015Q1($0.11)($0.13)$1.00 million$1.87 millionViewListenView Earnings Details
3/30/2015Q4 2014($0.11)($0.24)$0.10 million$0.49 millionViewN/AView Earnings Details
11/12/2014Q314($0.13)$76.60 million$3.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.11)($0.10)$1.93 million$0.0241 millionViewN/AView Earnings Details
3/27/2014Q4 2013($0.20)($0.15)$0.02 million$0.05 millionViewN/AView Earnings Details
11/12/2013($0.15)($0.22)$0.38 million$0.08 millionViewN/AView Earnings Details
8/14/2013Q213($0.17)$0.2780 million$0.3260 millionViewN/AView Earnings Details
5/15/2013Q113($0.11)($0.14)$0.52 million$0.1827 millionViewN/AView Earnings Details
3/28/2013Q4 2012($1.35)($1.65)ViewN/AView Earnings Details
12/20/2012Q312($0.10)$0.1040 million$0.1050 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Atossa Genetics (NASDAQ:ATOS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Atossa Genetics (NASDAQ ATOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 1.91%
Insider Trading History for Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics (NASDAQ ATOS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Kyle GuseCFOBuy10,000$0.34$3,400.00View SEC Filing  
4/17/2017H. Lawrence RemmelDirectorBuy2,500$0.63$1,575.00View SEC Filing  
4/1/2016H. Lawrence RemmelDirectorBuy1,500$0.33$495.00View SEC Filing  
3/9/2016Steven C QuayCEOBuy15,000$0.37$5,550.00View SEC Filing  
2/16/2016Shu-Chih ChenDirectorBuy15,000$0.53$7,950.00View SEC Filing  
1/19/2016Steven C QuayCEOBuy50,000$0.20$10,000.00View SEC Filing  
6/12/2015H. Lawrence RemmelDirectorBuy5,400$1.30$7,020.00View SEC Filing  
11/21/2013Gregory L WeaverDirectorBuy10,000$2.58$25,800.00View SEC Filing  
10/1/2013Steven C QuayCEOSell7,265$5.66$41,119.90View SEC Filing  
1/8/2013H. Lawrence RemmelDirectorBuy4,000$4.12$16,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Atossa Genetics (NASDAQ ATOS) News Headlines

Source:
DateHeadline
BRIEF-Atossa Genetics Announces 1 For 12 Reverse Stock SplitBRIEF-Atossa Genetics Announces 1 For 12 Reverse Stock Split
www.reuters.com - April 20 at 5:26 PM
Atossa to reverse split shares 1:12 todayAtossa to reverse split shares 1:12 today
seekingalpha.com - April 20 at 5:26 PM
Pre-Market Technical Scan on Healthcare Equities -- Atossa Genetics, Palatin Technologies, Quotient, and Avadel PharmaPre-Market Technical Scan on Healthcare Equities -- Atossa Genetics, Palatin Technologies, Quotient, and Avadel Pharma
www.bizjournals.com - April 20 at 8:18 AM
Atossa Genetics Announces 1 for 12 Reverse Stock SplitAtossa Genetics Announces 1 for 12 Reverse Stock Split
finance.yahoo.com - April 20 at 8:18 AM
Atossa Genetics Requests Shareholders to VoteAtossa Genetics Requests Shareholders to Vote
finance.yahoo.com - April 16 at 5:30 PM
Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male SubjectsAtossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male Subjects
globenewswire.com - April 12 at 8:24 AM
Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male SubjectsAtossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male Subjects
finance.yahoo.com - April 12 at 8:24 AM
Atossa Genetics Appoints Per Hall, MD, Ph.D. as Scientific AdvisorAtossa Genetics Appoints Per Hall, MD, Ph.D. as Scientific Advisor
finance.yahoo.com - March 27 at 5:19 PM
Atossa Genetics Launches Mens Breast Health Program - NasdaqAtossa Genetics Launches Mens' Breast Health Program - Nasdaq
www.nasdaq.com - March 22 at 8:19 AM
Atossa Genetics Launches Mens’ Breast Health ProgramAtossa Genetics Launches Mens’ Breast Health Program
finance.yahoo.com - March 22 at 8:19 AM
Atossa Genetics, Endoxifen Progressing, Breast Cancer, Analysts Target and Pipeline ReviewAtossa Genetics, Endoxifen Progressing, Breast Cancer, Analysts Target and Pipeline Review
finance.yahoo.com - March 13 at 8:17 AM
Atossa Genetics Announces 2017 Financial Results and Provides Company Update - NasdaqAtossa Genetics Announces 2017 Financial Results and Provides Company Update - Nasdaq
www.nasdaq.com - March 9 at 8:13 AM
Atossa Genetics Inc (ATOS) Sees Large Growth in Short InterestAtossa Genetics Inc (ATOS) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM
Quotidian Technical Highlights on Selected Healthcare Stocks -- Atossa Genetics, Palatin Technologies, Adamis ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Healthcare Stocks -- Atossa Genetics, Palatin Technologies, Adamis ... - PR Newswire (press release)
www.prnewswire.com - February 23 at 8:15 AM
Atossa Genetics Janet Rea Presenting On TRAP CAR-T and Related Cell Therapies at Adoptive T- Cell Therapy Symposium In San Francisco Feb. 15thAtossa Genetic's Janet Rea Presenting On ''TRAP CAR-T and Related Cell Therapies'' at Adoptive T- Cell Therapy Symposium In San Francisco Feb. 15th
finance.yahoo.com - February 14 at 9:18 AM
Atossa Genetics to Present at Adoptive T-Cell Therapy Symposium - Molecular Medicine Tri-Conference on Thursday February 15, 2018Atossa Genetics to Present at Adoptive T-Cell Therapy Symposium - Molecular Medicine Tri-Conference on Thursday February 15, 2018
finance.yahoo.com - February 13 at 9:21 AM
Vista Partners LLC: Vista Partners Updates Coverage on Four Dow 30 Companies: CAT, 3M, IBM & UNHVista Partners LLC: Vista Partners Updates Coverage on Four Dow 30 Companies: CAT, 3M, IBM & UNH
www.finanznachrichten.de - February 9 at 9:13 AM
Atossa Genetics Presents Additional Findings from its Phase 1 Study of Oral EndoxifenAtossa Genetics Presents Additional Findings from its Phase 1 Study of Oral Endoxifen
finance.yahoo.com - February 2 at 8:51 AM
Atossa Genetics Presents Additional Findings in Breast Cancer Study - Shares Up in After Hours TradingAtossa Genetics Presents Additional Findings in Breast Cancer Study - Shares Up in After Hours Trading
finance.yahoo.com - February 2 at 8:51 AM
Biotech Movers: Atossa Genetics Inc Raises on Back of Positive Early Clinical Data in Breast CancerBiotech Movers: Atossa Genetics Inc Raises on Back of Positive Early Clinical Data in Breast Cancer
finance.yahoo.com - February 2 at 8:51 AM
Atossa Genetics (ATOS) to Host Conference Call to Present Additional Findings from Phase 1 Study of Oral EndoxifenAtossa Genetics (ATOS) to Host Conference Call to Present Additional Findings from Phase 1 Study of Oral Endoxifen
www.streetinsider.com - February 1 at 9:09 AM
Atossa Genetics to Host Conference Call to Present Additional Findings from its Phase 1 Study of Oral Endoxifen Thursday February 1, 2018 at 4:30 pm ESTAtossa Genetics to Host Conference Call to Present Additional Findings from its Phase 1 Study of Oral Endoxifen Thursday February 1, 2018 at 4:30 pm EST
finance.yahoo.com - January 31 at 9:03 AM
2 Stocks Taking Cues for This Years Bull Market2 Stocks Taking Cues for This Year's Bull Market
finance.yahoo.com - January 29 at 3:40 PM
Today’s Research Reports on Trending Tickers: Atossa Genetics and PulmatrixToday’s Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix
finance.yahoo.com - January 29 at 9:10 AM
Vista Partners LLC: Atossa Genetics Receives Additional Sell Side Support & Coverage - Shares SurgeVista Partners LLC: Atossa Genetics Receives Additional Sell Side Support & Coverage - Shares Surge
www.finanznachrichten.de - January 26 at 3:39 PM
Atossa Genetics Receives Additional Sell Side Support & Coverage - Shares SurgeAtossa Genetics Receives Additional Sell Side Support & Coverage - Shares Surge
finance.yahoo.com - January 26 at 3:39 PM
Atossa Genetics (ATOS) Now Covered by Maxim GroupAtossa Genetics (ATOS) Now Covered by Maxim Group
www.americanbankingnews.com - January 26 at 8:16 AM
3 FREE Biotech/Healthcare Research Reports: Atossa Genetics Inc. (ATOS), Johnson & Johnson, Inc. (JNJ), & Pfizer Inc. (PFE)3 FREE Biotech/Healthcare Research Reports: Atossa Genetics Inc. (ATOS), Johnson & Johnson, Inc. (JNJ), & Pfizer Inc. (PFE)
finance.yahoo.com - January 23 at 5:30 PM
"The Bright Lights of 2017""The Bright Lights of 2017"
finance.yahoo.com - December 29 at 9:17 AM
Atossa Genetics President and CEO Issues Letter to Stockholders Highlighting Key Accomplishments and Outlines Milestones for 2018Atossa Genetics President and CEO Issues Letter to Stockholders Highlighting Key Accomplishments and Outlines Milestones for 2018
finance.yahoo.com - December 28 at 4:38 PM
Stock Update (NASDAQ:ATOS): Atossa Genetics Inc (ATOS) Welcomes Immunology Expert Dr. Carl Novina to Scientific Advisory BoardStock Update (NASDAQ:ATOS): Atossa Genetics Inc (ATOS) Welcomes Immunology Expert Dr. Carl Novina to Scientific Advisory Board
finance.yahoo.com - December 21 at 3:27 PM
Atossa Genetics (ATOS) Prices 5.3M Share Registered Direct Offering at $0.315/ShAtossa Genetics (ATOS) Prices 5.3M Share Registered Direct Offering at $0.315/Sh
www.streetinsider.com - December 21 at 8:25 AM
Atossa Genetics Appoints Carl Novina, MD, PhD as Scientific AdvisorAtossa Genetics Appoints Carl Novina, MD, PhD as Scientific Advisor
finance.yahoo.com - December 21 at 8:25 AM
Atossa Genetics Announces Pricing of $1.4 Million Registered Direct OfferingAtossa Genetics Announces Pricing of $1.4 Million Registered Direct Offering
finance.yahoo.com - December 20 at 3:25 PM
Atossa Genetics Inc (ATOS) Cashes Out; Shares Take a HitAtossa Genetics Inc (ATOS) Cashes Out; Shares Take a Hit
finance.yahoo.com - December 20 at 3:25 PM
Atossa Genetics Inc. (ATOS) Short Interest UpdateAtossa Genetics Inc. (ATOS) Short Interest Update
www.americanbankingnews.com - December 15 at 3:08 AM
Blog Exposure – Neogen’s Shareholders Set to Receive Additional Stock as the Company Announces Stock SplitBlog Exposure – Neogen’s Shareholders Set to Receive Additional Stock as the Company Announces Stock Split
finance.yahoo.com - December 12 at 8:43 AM
"Will the Bull Market Continue to Run?""Will the Bull Market Continue to Run?"
finance.yahoo.com - November 29 at 3:25 PM
Atossa Genetics Inc. Forecasted to Earn FY2017 Earnings of ($0.84) Per Share (ATOS)Atossa Genetics Inc. Forecasted to Earn FY2017 Earnings of ($0.84) Per Share (ATOS)
www.americanbankingnews.com - November 17 at 9:44 PM
Atossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company UpdateAtossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company Update
finance.yahoo.com - November 14 at 4:38 PM
BRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filingBRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filing
www.reuters.com - November 9 at 5:23 PM
Atossa Genetics Applauds Newly-Introduced Federal Legislation Requiring That Breast Density Be Reported To Physicians and PatientsAtossa Genetics Applauds Newly-Introduced Federal Legislation Requiring That Breast Density Be Reported To Physicians and Patients
finance.yahoo.com - November 6 at 3:50 PM
Atossa Genetics Inc. (ATOS) Set to Announce Earnings on MondayAtossa Genetics Inc. (ATOS) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
BRIEF-L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26BRIEF-L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26
www.reuters.com - November 3 at 9:34 PM
"Economy Still Growing Strong?""Economy Still Growing Strong?"
finance.yahoo.com - October 31 at 5:21 PM
Atossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment OptionAtossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment Option
finance.yahoo.com - October 30 at 5:12 PM
Atossa Genetics (ATOS) Pricing of 11.5M Public Offering of Common Stock at $0.44/ShareAtossa Genetics (ATOS) Pricing of 11.5M Public Offering of Common Stock at $0.44/Share
www.streetinsider.com - October 27 at 11:22 PM
Atossa Genetics (ATOS) Presents On Preliminary Oral Endoixifen Phase 1 Results - SlideshowAtossa Genetics (ATOS) Presents On Preliminary Oral Endoixifen Phase 1 Results - Slideshow
seekingalpha.com - October 27 at 11:22 PM
Atossa Genetics Announces Pricing of $5.1 Million Public Offering of Common StockAtossa Genetics Announces Pricing of $5.1 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 10:04 AM
Atossa Genetics Inc (ATOS) Tumbles After Stock Offering Prices at Deep DiscountAtossa Genetics Inc (ATOS) Tumbles After Stock Offering Prices at Deep Discount
finance.yahoo.com - October 26 at 10:04 AM

SEC Filings

Atossa Genetics (NASDAQ:ATOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Atossa Genetics (NASDAQ:ATOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Atossa Genetics (NASDAQ ATOS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.